Lithium Therapy for Bipolar Disorder and Its Clinical Management
This community focuses on the clinical application of lithium salts, primarily for the treatment and maintenance of bipolar disorder, while also investigating its safety profile, toxicology, and emerging roles in neurodegenerative conditions.
The research is dominated by clinical trials and case reports detailing lithium carbonate and lithium chloride regimens for bipolar patients. A significant portion of the work addresses the management of lithium toxicity, chronic kidney disease, and diabetes insipidus associated with long-term use. The literature also explores lithium’s effects on glycogen synthase kinase-3β and its potential utility in Alzheimer’s disease, alongside studies on eating disorders and depression in older adults. The field relies heavily on systematic reviews and meta-analyses to evaluate therapeutic response and risk factors, with a strong emphasis on pharmacokinetics and patient safety monitoring in diverse clinical populations.
The largest share of the community's output is found in lithium research, accounting for 5.3% of all lithium research and representing 5,564 papers within this group.
The community comprises 8,557 papers, published most frequently in the American Journal of Psychiatry, The Lancet, and the British Journal of Psychiatry.
Recent work continues to examine lithium’s interaction with newer diabetes medications and its long-term cardiovascular and mortality outcomes in bipolar patients, alongside ongoing investigations into its molecular mechanisms in Alzheimer’s disease and depression.